Testing an app for insulin dosing
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests the EkiYou smartphone app to help calculate your mealtime insulin dose. You need to have diabetes, use both a long-acting and a short-acting insulin pen, and be comfortable with a CGM and a smartphone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have type 1, type 2, or pancreas-related diabetes and be on a basal-bolus insulin routine for at least 6 months.
- You must use specific rapid- and long-acting insulins like Novorapid, Lantus, etc.
- You must have been using a compatible continuous glucose monitor (CGM) like Dexcom G6 or FreeStyle Libre for at least 3 months.
- You need a smartphone (Android 5.0+ or iOS 12.0+) that can receive CGM data and is connected to the internet.
- You must be able to read and use the smartphone app without visual issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a smartphone app that helps people with type 1 diabetes predict their blood sugar and decide how much insulin to take. It may be a good fit if you already use multiple daily insulin injections and a continuous glucose monitor.
This trial studies a smartphone system that helps people with diabetes decide how much insulin to take. It is for people who use insulin injections or are starting basal insulin, and it uses a continuous glucose monitor to guide dosing.
This study tests an app-based diabetes education program for people with type 1 diabetes. It aims to see if the app can help you manage your blood sugar levels better using insulin pens and a continuous glucose monitor.
This 8-week study tests whether using a smartphone app called SnapD along with a continuous glucose monitor (a small sensor that tracks your blood sugar throughout the day) helps people with type 2 diabetes manage their condition better. You'll keep taking your current diabetes medications without changes.
This trial tests MODI, a smartphone app that helps automatically adjust your insulin doses based on blood sugar readings from a continuous glucose monitor. The study checks if this system is safe and helps people with type 1 or type 2 diabetes manage their blood sugar better.
This trial tests a smart phone-based system that helps doctors monitor diabetes and adjust insulin treatment. It could make blood sugar control easier for people with type 2 diabetes.
Hear when a new Diabetes Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.